MAR-FINGOLIMOD CAPSULE

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE)

可用日期:

MARCAN PHARMACEUTICALS INC

ATC代码:

L04AA27

INN（国际名称）:

FINGOLIMOD

剂量:

0.5MG

药物剂型:

CAPSULE

组成:

FINGOLIMOD (FINGOLIMOD HYDROCHLORIDE) 0.5MG

给药途径:

ORAL

每包单位数:

28

处方类型:

Prescription

治疗领域:

Immunomodulatory Agents

產品總結:

Active ingredient group (AIG) number: 0152886001; AHFS:

授权状态:

APPROVED

授权日期:

2019-03-11

产品特点

Page 1 of 64
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MAR-FINGOLIMOD
Fingolimod capsules
Capsules, 0.5 mg fingolimod (as fingolimod hydrochloride), Oral
Manufacturer’s Standard
Sphingosine 1-phosphate receptor modulator
Marcan Pharmaceuticals Inc.
2 Gurdwara Road, Suite #112
Ottawa, ON, K2E 1A2
Date of Initial Authorization:
MAR 11, 2019
Date of Revision:
MAR 03, 2022
Submission Control Number: 257291
Page 2 of 64
RECENT MAJOR LABEL CHANGES
2 Contraindications
03/2022
4 Dosage and Administration
03/ 2022
7 Warnings and Precautions
03/ 2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES……………………………………………………………………………………………….2
TABLE OF
CONTENTS…………………………………………………………………………………………………………………2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
......................................................................................................................
4
1.2
Geriatrics
.......................................................................................................................
4
2
CONTRAINDICATIONS
.....................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.....................................................................................
5
4.1
Dosing Considerations
..................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
............................................................. 7
4.4
Administration
....................................................................